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Abstract A number of N-alkyl indole or indazole-3-car-
bonyl analogs, with modified chemical structures, are dis-
tributed throughout the world as synthetic cannabinoids.
Like synthetic cannabinoids, cathinone analogs are also
abused and cause serious problems worldwide. Acute
deaths caused by overdoses of these drugs have been re-
ported. Various analytical methods that can cope with the
rapid changes in chemical structures are required for rou-
tine analysis and screening of these drugs in seized and
biological materials for forensic and clinical purposes.
Although many chromatographic methods to analyze each
drug have been published, there are only a few articles
summarizing these analytical methods. This review pre-
sents the various colorimetric detections, immunochemical
assays, gas chromatographic–mass spectrometric methods,
and liquid chromatographic–mass spectrometric methods
proposed for the analysis of synthetic cannabinoids and
cathinones.
Keywords Synthetic cannabinoids  Cannabimimetics 
Cathinones  GC–MS-MS  LC–MS-MS  Analytical
methods
Abbreviations
A-796260 [1-[2-(4-Morpholinyl)ethyl]-1H-
indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone
A-834735 [1-[(Tetrahydro-2H-pyran-4-
yl)methyl]-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)-
methanone
AB-001 Adamantan-1-yl(1-pentyl-1H-indol-
3-yl)methanone
AB-005 [1-[(1-Methyl-2-piperidinyl)methyl]-
1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone
AB-CHMINACA N-[(1S)-1-(Aminocarbonyl)-
2-methylpropyl]-1-
(cyclohexylmethyl)-1H-indazole-3-
carboxamide
AB-FUBINACA N-(1-Amino-3-methyl-1-oxobutan-2-
yl)-1-(4-fluorobenzyl)-1H-indazole-
3-carboxamide
AB-PINACA N-(1-Amino-3-methyl-1-oxobutan-2-
yl)-1-pentyl-1H-indazole-3-
carboxamide
ADB-FUBINACA N-(1-Amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide
ADBICA N-(1-Amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-pentyl-1H-indole-
3-carboxamine
ADB-PINACA N-(1-Amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide
AM-1220 [1-[(1-Methylpiperidin-2-yl)methyl]-
1H-indol-3-yl]-(naphthalen-1-
yl)methanone
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AM-1248 Adamantan-1-yl[1-[(1-methyl-2-
piperidinyl)methyl]-1H-indol-3-
yl]methanone
AM-1241 (2-Iodo-5-nitrophenyl)-[1-(1-
methylpiperidin-2-ylmethyl)-1H-
indol-3-yl]methanone
AM-2201 [1-(5-Fluoropentyl)-1H-indol-3-yl]-
1-naphthalenylmethanone
AM-2233 (2-Iodophenyl)[1-[(1-methyl-2-
piperidinyl)methyl]-1H-indol-3-yl]-
methanone
AM-679 (2-Iodophenyl)(1-pentyl-1H-indol-3-
yl)methanone
AM-694 1-[(5-Fluoropentyl)-1H-indol-3-yl]-
(2-iodophenyl)methanone
AMB Methyl (1-pentyl-1H-indazole-3-
carbonyl)-L-valinate
APICA N-(1-Adamantyl)-1-pentyl-1H-
indole-3-carboxamide
APINACA N-(1-Adamantyl)-1-pentyl-1H-
indazole-3-carboxamide
Cathinone 2-Amino-1-phenylpropan-1-one
CI Chemical ionization
EI Electron ionization
ELISA Enzyme-linked immunosorbent
assay
ESI Electrospray ionization
FDU-PB-22 Naphthalen-1-yl 1-(4-fluorobenzyl)-
1H-indole-3-carboxylate
5F-PB-22 1-(5-Fluoropentyl)-8-quinolinyl
ester-1H-indole-3-carboxylic acid
FUB-PB-22 Quinolin-8-yl-1-(4-fluorobenzyl)-1H-
indole-3-carboxylate
GC Gas chromatography
GC–MS Gas chromatography–mass
spectrometry
GC–MS-MS Gas chromatography–tandem mass
spectrometry
HU-210 3-(1,10-Dimethylheptyl)-
6aR,7,10,10aR-tetrahydro-1-
hydroxy-6,6-dimethyl-6H-
dibenzo[b,d]pyran-9-methanol
JWH-015 1-Naphthalenyl(2-methyl-1-propyl-
1H-indol-3-yl)methanone
JWH-018 1-Naphthalenyl(1-pentyl-1H-indol-3-
yl)methanone
JWH-019 1-Naphthalenyl(1-hexyl-1H-indol-3-
yl)methanone
JWH-030 1-Naphthalenyl(1-pentyl-1H-pyrrol-
3-yl)methanone
JWH-073 1-Naphthalenyl(1-butyl-1H-indol-3-
yl)methanone
JWH-200 1-Naphthalenyl[1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-
yl]methanone
JWH-203 2-(2-Chlorophenyl)-1-(1-pentyl-1H-
indol-3-yl)ethanone
JWH-250 2-(2-Methoxyphenyl)-1-(1-pentyl-
1H-indol-3-yl)ethanone
JWH-251 2-(2-Methylphenyl)-1-(1-pentyl-1H-
indol-3-yl)ethanone
JWH-307 [5-(2-Fluorophenyl)-1-pentyl-1H-
pyrrol-3-yl](naphthalene-1-
yl)methanone
LC Liquid chromatography
LC–MS Liquid chromatography–mass
spectrometry
LC–MS-MS Liquid chromatography–tandem mass
spectrometry
LLE Liquid–liquid extraction
LOD Limit of detection
LOQ Limit of quantification
MAM-2201 [1-(5-Fluoropentyl)-1H-indol-3-
yl](4-methyl-1-
naphthalenyl)methanone
MDPBP 30,40-Methylenedioxy-a-
pyrrolidinobutiophenone
MDPPP 30,40-Methylenedioxy-a-
pyrrolidinopropiophenone
MDPV 3,4-Methylenedioxypyrovalerone
MN-18 N-1-Naphthalenyl-1-pentyl-1H-
indazole-3-carboxamide
MOPPP 40-Methoxy-a-
pyrrolidinopropiophenone
NM-2201 Naphthalen-1-yl 1-(5-fluoropentyl)-
1H-indole-3-carboxylate
NMR Nuclear magnetic resonance
NNEI N-1-Naphthalenyl-1-pentyl-1H-
indole-3-carboxamide
MPBP 40-Methyl-a-pyrrolidinobutiophenone
MPHP 40-Methyl-a-
pyrrolidinohexanophenone
MPPP 40-Methyl-a-
pyrrolidinopropiophenone
MRM Multiple reaction monitoring
MS Mass spectrometry
MS-MS Tandem mass spectrometry
NPB-22 8-Quinolinyl 1-pentyl-1H-indazole-
3-carboxylate
a-PBP a-Pyrrolidinobutiophenone
a-PHP a-Pyrrolidinohexanophenone
PP Protein precipitation
a-PPP a-Pyrrolidinopropiophenone
PTFE Polytetrafluoroethylene
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PV8 1-Phenyl-2-(pyrrolidin-1-yl)heptan-
1-one
PV9 1-Phenyl-2-(pyrrolidin-1-yl)octan-1-
one
a-PVP 1-Phenyl-2-(pyrrolidin-1-yl)pentan-
1-one, a-pyrrolidinovalerophenone
PX1 (S)-N-(1-Amino-1-oxo-3-
phenylpropan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-
carboxamide
QUPIC Quinolin-8-yl 1-pentyl-1H-indole-3-
carboxylate
QUCHIC Quinolin-8-yl 1-(cyclohexylmethyl)-
1H-indole-3-carboxylate
RCS-4 (4-Methoxyphenyl)(1-pentyl-1H-
indol-3-yl)methanone
SDB-005 Naphthalen-1-yl 1-pentyl-1H-
indazole-3-carboxylate
SIM Selected ion monitoring
SPE Solid-phase extraction
SPME Solid-phase microextraction
SRM Selected reaction monitoring
THJ-018 1-Naphthalenyl(1-pentyl-1H-indazol-
3-yl)methanone
THJ-2201 [1-(5-Fluoropentyl)-1H-indazol-3-
yl](naphthalen-1-yl)methanone
TLC Thin-layer chromatography
TOFMS Time-of-flight mass spectrometry
UV Ultraviolet
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone
XLR-11 [1-(5-Fluoropentyl)-1H-indol-3-
yl](2,2,3,3-
tetramethylcyclopropyl)methanone
XLR-12 (2,2,3,3-Tetramethylcyclopropyl)[1-
(4,4,4-trifluorobutyl)-1H-indol-3-
yl]methanone
Introduction
Currently, many illegal drugs are abused worldwide, with
serious social problems arising as a consequence. Although
various stimulants and narcotics have been in use to date,
new drugs targeting cannabinoid receptors have been
abused since their existence in herbal mixtures was dis-
closed in 2008 [1]. HU-210, a synthetic classical
cannabinoid, and cyclohexylphenols were commonly used
as recreational drugs, but mainstream use has since chan-
ged to N-alkyl indole-3-carbonyl derivatives, such as drugs
of the JWH and AM series (Fig. 1), because their activities
are stronger than those of the conventional cannabinoids.
These compounds are called cannabimimetics or synthetic
cannabinoids and can be purchased as ‘‘spice’’ or ‘‘K2’’ in
the drug market or via the Internet. Cathinones, also known
as ‘‘bath salts’’ or ‘‘plant food,’’ are psychoactive drugs and
are also abused as recreational drugs. The parent com-
pound, cathinone, is a well-known stimulant, and can be
isolated from the khat plant or produced by synthetic
means. Cathinone analogs with high selectivity and strong
activity for serotonin receptors and monoamine trans-
porters have been distributed in the drug market (Fig. 2).
The prevalence of cannabinoid and cathinone abuse in
many countries has been reviewed elsewhere [2–7].
Although the same substances are distributed throughout
the world, the times at which they are abused tend to vary
depending on whether the substances are controlled by local
laws. As shown in the reviews [2–7], new analogs appear in
the drug market just after the preceding drug comes under
regulation. Although many such substances are controlled in
countries throughout the world, the regulations are usually
limited by the structures of the drugs. Therefore, when the
structure of a side chain or substitution is slightly different
from that of the regulated drug, the analog is regarded as
being beyond the scope of the regulation. These emerging
drugs always show psychoactive actions because their che-
mical structures are similar to those of the drugs being con-
trolled. However, the detailed pharmacological activities of
these analogs are not known, which makes access easy and
use of these drugs very dangerous to human health.
Although many researchers have focused on the devel-
opment of detection methods, only a few analytical reviews
that summarize the systematic identification and quantifi-
cation techniques for these drugs have appeared [8–10]. In
this review, we summarize the various techniques for the
detection of synthetic cannabinoids and cathinones that
have been published up to 2014, including colorimetric,
immunochemical, and chromatographic methods.
Synthetic cannabinoids
Colorimetric detection
The Duquenois–Levine color test, which is used to identify
classical cannabinoids such as D9-tetrahydrocannabinol, is
negative for the synthetic cannabimimetics. The van Urk
color test, which is used to identify indole-containing drugs
of abuse, is also negative for these compounds. The use of
2,4-dinitrophenylhydrazine, which reacts with a keto moi-
ety, is capable of reacting with synthetic cannabimimetics,
such as the naphthoylindole, phenylacetylindole, ben-
zoylindole, and cyclopropylindole classes, either in powder
form or adsorbed onto plant material, and a positive test
solution turns from yellow to orange. Although the LOD
concentration was not detailed in the article, the solution
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tested contained at least 10 mg of cannabimimetic powder
suspended in methanol (1 ml) [11]. The Marquis reagent,
which reacts with all nitrogen-containing drugs, is positive
for cyclohexylphenols and the JWH series. Although Dra-
gendorff reagent is also positive for the JWH series, its LOD
concentration is higher than that of Marquis reagent. Fast
blue BB reacts with cyclohexylphenols, and the LOD con-
centration is not lower than that of Marquis reagent [12].
Iodoplatinate is also used as a detection reagent after TLC
[13]. Although it is possible to detect synthetic cannabinoids
with each reagent in these screening tests, it is difficult to
detect small amounts or mixtures of synthetic cannabinoids.
Immunochemical detection
ELISAs developed in-house could be calibrated at 5 ng/ml
with the 5-OH and 4-OH metabolites of JWH-018 and
JWH-250, respectively, and evaluated for the detection of
synthetic cannabinoids in urine [14]. Recently, some
commercially available immunoassay kits, such as Drug-
Check K2/Spice Test, DrugSmart Cassette, and RapiCard
InstaTest, have been developed for the detection of these
drugs in urine. These devices are more useful than the
colorimetric methods, because they do not require special
reagents or tools, and the results are obtained easily and
Indole 3-carbonyl derivatives
R1 R2 R3
JWH-015 n-Propyl Methyl 1-Naphthyl
JWH-018 n-Pentyl H 1-Naphthyl
AM-1220 (1-Methyl-2-piperidinyl)methyl H 1-Naphthyl
JWH-200 2-(4-Morpholinyl)ethyl H 1-Naphthyl
JWH-203 n-Pentyl H 2-Chloro-benzyl
JWH-250 n-Pentyl H 2-Methoxy-benzyl
JWH-251 n-Pentyl H 2-Methoxy-benzyl
RCS-4 n-Pentyl H 4-Methoxy-phenyl
AB-001 n-Pentyl H Adamantyl
AM-1248 (1-Methyl-2-piperidinyl)methyl H Adamantyl
AM-679 n-Pentyl H 2-Iodo-phenyl
AM-694 5-Fluoro-n-pentyl H 2-Iodo-phenyl
AM-2233 (1-Methyl-2-piperidinyl)methyl H 2-Iodo-phenyl
AM-1241 (1-Methyl-2-piperidinyl)methyl H 2-Iodo-5-nitro-phenyl
- a 5-Fluoro-n-pentyl H 3-Pyridinoyl
N
R3
O
R1
R2
R1
UR-144 n-Pentyl
XLR-11 5-Fluoro-n-pentyl
XLR-12 4,4,4-Trifluoro-butyl
AB-005 (1-Methyl-2-piperidinyl)methyl
A-834735 (Tetrahydro-2H-pyran-4-yl)methyl
A-796260 2-(4-Morpholinyl)ethyl
N
O
R1
R2 N
O
R1 R1 R2
JWH-030 n-Pentyl H
JWH-307 n-Pentyl 2-Fluoro-phenyl
Indazole 3-carbonyl derivativePyrrole 3-carbonyl derivatives
N
N
R2
O
R1
R1 R2
THJ-2201 5-Fluoro-n-pentyl 1-Naphthyl
a No abbreviated name available
Fig. 1 Structures of synthetic cannabinoids
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quickly. The devices also can detect older types of syn-
thetic cannabinoids, such as JWH-018 or JWH-073, but,
unfortunately, new designer drugs such as QUPIC and AB-
CHMINACA cannot be detected.
GC–MS detection
Typical mass spectra of synthetic cannabinoids are shown
in Fig. 3. Molecular (M?) and/or fragment ions observed
by full scan data acquisition of GC–MS reflect the struc-
tures of the synthetic cannabinoids [13, 15, 16]. As shown
in Fig. 4, the fragmentation pathways of naphthoylindoles
have been well studied for the identification of synthetic
cannabinoids by GC–MS [12, 15]. Therefore, the identifi-
cation of synthetic cannabinoids is facilitated by compar-
ison of the spectra with commercial and open databases.
In naphthoylindoles, the carbonyl group fragment ions,
which are caused by a-cleavage of the alkylamino group of
R1 R2
APICA n-Pentyl Adamantyl
5F-APICA 5-Fluoro-n-pentyl Adamantyl
NNEI(MN-24) n-Pentyl 1-Naphthyl
5F-NNEI 5-Fluoro-n-pentyl 1-Naphthyl
R1 R2 R3
AB-PINACA n-Pentyl i-Propyl NH2 
5F-AB-PINACA 5-Fluoro-n-pentyl i-Propyl NH2
ADB-PINACA n-Pentyl t-Butyl NH2
AB-FUBINACA 4-Fluoro-benzyl i-Propyl NH2
ADB-FUBINACA 4-Fluoro-benzyl t-Butyl NH2
AB-CHMINACA Cyclohexylmethyl i-Propyl NH2
AMB n-Pentyl i-Propyl Methoxy
5F-AMB 5-Fluoro-n-pentyl i-Propyl Methoxy
N
N
N
H
O
R1
R2
R3O
N
N
H
O
R1
R2
R3O
R1 R2 R3
ADBICA n-Pentyl t-Butyl NH2 
PX1 5-Fluoro-n-pentyl Benzyl NH2 
R1 R2
NM-2201 5-Fluoro-n-pentyl 1-Naphthyl
FDU-PB-22 4-Fluoro-benzyl 1-Naphthyl
QUPIC(PB-22) n-Pentyl 8-Quinolinyl
5F-PB-22 5-Fluoro-n-pentyl 8-Quinolinyl
QUCHIC(BB-22) Cyclohexylmethyl 8-Quinolinyl
FUB-PB-22 4-Fluoro-benzyl 8-Quinolinyl
N
N
H
O
R1
R2
N
N
N
H
O
R1
R2
N
O
R2
O
R1
N
N
O
R2
O
R1
R1 R2
5F-SDB-005 5-Fluoro-n-pentyl 1-Naphthyl
5F-NPB-22 5-Fluoro-n-pentyl 8-Quinolinyl
Indole 3-carbonylamide derivatives Indazole 3-carbonylamide derivatives
Indole 3-carbonylester derivatives
Indazole 3-carbonylester derivatives
R1 R2
APINACA n-Pentyl Adamantyl
5F-APINACA 5-Fluoro-n-pentyl Adamantyl
MN-18 n-Pentyl 1-Naphthyl
5F-MN-18 5-Fluoro-n-pentyl 1-Naphthyl
Fig. 1 continued
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the indole, are typically observed. In addition, [M-17]? is
certainly observed in naphthoylindoles. For example,
fragment ions at m/z 284 and 214 are observed in JWH-
018, corresponding to those of the indole moiety caused by
a-cleavage of the N-pentyl of indole and naphthoyl.
Fragment ions at m/z 127 and 155 are observed in JWH-
018, corresponding to the naphthalene group caused by the
a-cleavage of the carbonyl group. Moreover, ions at
m/z 324 are observed as [M-17]? (Fig. 3a). Like naph-
thoylindoles, fragment ions caused by a-cleavage of the
alkylamino group of the indole and carbonyl groups are
shown, although [M-17]? is not observed for benzoylin-
doles. For example, fragment ions at m/z 264 and 214 are
observed for RCS-4, caused by a-cleavage of N-pentyl of
the indole and 4-methoxybenzoyl. The ions at m/z 127 and
155, which are caused by naphthyl and naphthoyl moieties
of naphthoylindoles (Fig. 3a), and the ion at m/z 135
caused by the 4-methoxybenzoyl moiety (Fig. 3b) are
useful as precursor ions for identification of these drugs by
GC–MS-MS. On the other hand, the methylpiperidine
moiety is bound to the nitrogen of the indole, and the ion at
m/z 98 is observed as the base peak (Fig. 3d). Unlike
naphthoyl and benzoyl indoles, the base peak of the
fragment ion caused by the N-alkylindole 3-carbonyl
moiety for phenylacetyl (Fig. 3c), cyclopropyl, or ada-
mantyl (Fig. 3f) indoles, is only shown in each full scan
spectrum. Analogs, in which the indole skeleton is changed
to an indazole, such as THJ-018, have also appeared on the
market. In these analogs, molecular and N-dealkylated ions
are typically observed in the spectrum (Fig. 3e).
Recently, amide- or ester-type analogs bonded with an N-
alkylindole or N-alkylindazole 3-carbonyl moiety have ap-
peared on the market [17, 18]. In these analogs, the abun-
dance of the molecular ion is low, and the fragment ion
caused by the indoyl (or indazoyl) moiety is observed as a
base peak (Fig. 3f–k). Although the fragment ion caused by
elimination of the terminal CO–NH2 is lower than that of the
cleavage of the amide moiety in indole analogs, such as
ADBICA (Fig. 3h) [19], the fragment ion caused by
elimination of terminal CO–NH2 is as intense as that of the
cleavage of the amide moiety in indazole analogs, such as
ADB-PINACA and AB-CHMINACA (Fig. 3j, k) [20]. The
substitution of the indole skeleton with the indazole moiety,
such as in THJ-018 and THJ-2201 [21], has also been ob-
served in these analogs. In these analogs, molecular and N-
dealkylated ions are typically observed in the spectrum.
Name R1 R2 R3 R4 R5
Cathinone Methyl H H H H
Methcathinone Methyl Methyl H H H
N,N-Dimethylcathinone Methyl Methyl Methyl H H
Mephedrone Methyl Methyl H Methyl H
3,4-Dimethylmethcathinone Methyl Methyl H Methyl Methyl
4-Ethylmethcathinone Methyl Methyl H Ethyl H
Methylone Methyl Methyl H Methylenedioxy
Ethcathinone Methyl Ethyl H H H
Ethylone Methyl Ethyl H Methylenedioxy
Amfepramone Methyl Ethyl Ethyl H H
Buphedrone Ethyl Methyl H H H
4-Methylbuphedrone Ethyl Methyl H Methyl H
Butylone Ethyl Methyl H Methylenedioxy
N-Ethylbuphedrone Ethyl Ethyl H H H
Eutylone Ethyl Ethyl H Methylenedioxy
Pentedrone Propyl Methyl H H H
α-Ethylaminopentiophenone Propyl Ethyl H H H
Name R1 R2 R3
α-PPP Methyl H H
α-PBP Ethyl H H
α-PVP Propyl H H
α-PHP Butyl H H
PV8 Pentyl H H
PV9 Hexyl H H
MPPP Methyl Methyl H
MOPPP Methyl Methoxy H
MPBP Ethyl Methyl H
Pyrovalerone Propyl Methyl H
Naphyrone Propyl Phenyl
MPHP Butyl Methyl H
MDPPP Methyl Methylenedioxy
MDPBP Ethyl Methylenedioxy
MDPV Propyl Methylenedioxy
R1
R5
R4
R2
N
R3O
R1
R3
R2
N
O
Fig. 2 Structures of cathinones
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For example, in the simultaneous analysis of synthetic
cannabinoid species, 10 mg of ground powder of the dried
leaves was extracted with 10 ml of methanol under ultra-
sonication for 10 min. The extracts were centrifuged for
5 min at 3,000 rpm, and the supernatants were filtered and
used for GC–MS analysis. The LODs were 0.5–1.0 mg/l, and
linearity was obtained at concentrations up to 100 mg/l [16].
In another article [22], herbal samples (approximately
50 mg) were put into 10-ml headspace vials, and the vials
were capped with 20-mm magnetic crimp seal caps with
PTFE/silicone septa. The samples were incubated at 200 C
with pulse-agitation at 250 rpm. A StableFlex carboxen/
polydimethylsiloxane fiber was inserted into the headspace
for 5 min for extraction. The fiber was then injected into the
GC inlet for 15 min to desorb the analytes. The LOD of
synthetic cannabinoid in the samples was at least 20 lg.
The tentative identification of synthetic cannabinoids
appears easy, but similar mass spectra are sometimes ob-
tained by GC–MS because regio- and ring-substituted ana-
logs are still distributed on the market. The misidentification
of these analogs arises when using only the information from
the mass spectra. When tandem and high-resolution MS are
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Fig. 3 Typical mass spectra of synthetic cannabinoids obtained by GC–MS. a JWH-018, b RCS-4, c JWH-250, d AM-1220, e THJ-018,
f APICA, g NNEI, h ADBICA, i QUPIC (PB-22), j ADB-PINACA, k AB-CHMINACA
Forensic Toxicol (2015) 33:175–194 181
123
used to identify the conformational isomers or regioisomers,
such misidentification does not occur [23–28]. Moreover,
identification of cyclopropyl or ester analogs, such as UR-
144 or QUPIC, is usually not possible because cyclopropyl
analogs are heat-unstable and are easily degraded in the in-
jection port of the GC instrument [29, 30].
LC–MS-MS detection
Many research groups have used LC–MS-MS for deter-
mination of synthetic cannabinoids in herbs and biological
samples, and some have studied the fragmentation of
synthetic cannabinoids in detail [15, 31]. The probable
fragmentation pathways are shown in Fig. 4. Because the
protonated molecular ion is only observed by LC–MS, and
the information acquired by LC–MS is lesser than that for
GC–MS, it is necessary to obtain other data that reflect the
chemical structures by LC–MS-MS or TOFMS. Fragment
ions are observed by product ion scanning when the pro-
tonated molecular ion is used as the precursor ion. In
naphthoylindole, ions at m/z 127 and 155 are generated by
naphthyl and naphthoyl moieties. However, information
about the indole moiety tends to be not revealed by LC–
MS-MS. On the other hand, the N-alkyl moiety of a
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synthetic cannabinoid is mainly modified for excretion into
urine as a metabolite. Therefore, LC–MS-MS is a useful
methodology to search for metabolites of synthetic
cannabinoids in urine.
Recently, packages containing mixtures of multiple
synthetic cannabinoids have been sold commercially, even
though the package ingredients have been largely unknown
to both sellers and buyers. In this aspect, the LC–MS-MS
screening method is helpful in some estimation of the in-
gredients. Kneisel and Auwa¨rter [32] demonstrated the si-
multaneous detection of 30 synthetic cannabinoids in
serum; the LODs and LOQs were 0.01–2.0 and 0.1–2.0 ng/
ml, respectively. There are many applications for analysis
of synthetic cannabinoids in urine, hair, and oral fluids [33–
37]. The typical published methods for analysis of syn-
thetic cannabinoids in biological materials are summarized
in Table 1 [38–54]. Simple LLE is usually used for the
extraction of synthetic cannabinoids from biological ma-
terials because of the high hydrophobicity of the drugs. The
chromatographic conditions are generally simple and do
not require a special technique; octadecyl-type columns
were used as analytical columns and analyses were per-
formed in gradient mode.
The identification of an unknown drug in a biological
material without information is almost always difficult,
even if analysis is carried out with LC–MS-MS. To
overcome this situation, high-resolution MS or TOFMS
become helpful tools for tentative estimation of parent
drugs and their metabolites of synthetic cannabinoids.
To clarify the chemical structure of an unknown drug in
a herbal blend product that contains more than several
milligrams of the drug, GC–MS, LC–MS-MS, and high-
resolution MS (or TOFMS) can be used to estimate the
structure. The target compound is then purified by pre-
parative LC or preparative TLC to obtain more than several
milligrams of the compound of high purity, which is then
analyzed by NMR spectroscopy [17–21]. The detailed
chemical structure can be elucidated by the above laborious
instrumental analyses.
Cathinones
Colorimetric detection
The Marquis reagent, which reacts with all nitrogen-con-
taining drugs, is negative for cathinones, such as cathinone
and mephedrone, but is positive for cathinone analogs that
have a methylenedioxy moiety in each molecule. The
cathinone analogs with a methylenedioxy moiety also react
with the Chen reagent, which changes to orange in positive
tests. Although the LOD concentration is not reported, the
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Fig. 4 Probable fragmentation pathways of synthetic cannabinoids by electrospray ionization and electron ionization (modified from references
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described test solution contained cathinone powder (at
least 10 mg) suspended in methanol (1 ml) [55–57]. The
combination of Marquis, Ehrlich, Simon, Lieberman–
Burehand, and Mandelin reagents is useful for the detec-
tion of cathinones in samples. Like synthetic cannabinoids,
the identification of these compounds, of course, cannot be
performed using these methods; moreover, the detection of
small amounts or mixtures of cathinones is difficult.
Immunochemical detection
Some researchers have tried to detect cathinones in urine
using immunoassay technology [58, 59]. Some articles
revealed false-positive results by immunoassays; for ex-
ample, MDPV was cross-reactive with phencyclidine [60].
Therefore, specific detection of cathinones by a commer-
cial immunoassay is not yet possible.
GC–MS-MS detection
Mass spectral profiles of cathinones are very simple in the
positive mode of GC–MS, because only the base peak
originating from the immonium ion in each molecule is
observed. The probable fragmentation pathways of cathi-
nones are described in previous articles [61–64] and are
shown in Fig. 5. However, this phenomenon makes the
identification of cathinones difficult. To help identify
cathinones, other information, such as tandem mass spec-
trometric data, are usually used because more structural
information about the molecule is obtained.
Zuba [61] introduced the systematic identification of
cathinones using the mass spectra obtained. First, it should
be checked whether the molecular ion is observed. The
immonium ion (m/z = 16 ? 14 n, n = 1, 2, 3,…) is then
checked in the EI spectrum. If the immonium ion is found
in the spectrum, the substance could be a straight-chained
cathinone. If not, it is checked whether the ion for a
pyrrolidine ring is observed (m/z = 70 ? 14 n, n = 1, 2,
3,…). If this ion is found in the spectrum, the substance
could be a cathinone with a pyrrolidine ring in the mole-
cule [61]. There are various regioisomers in cathinones. To
identify the cathinones, it is necessary to assign both the
location and length of the bonded alkyl chain. Moreover,
the ring-substituted moiety is also needed to be assigned.
Zuba [61] demonstrated the following rules: the fragment
ions reflecting the ring-substituted moiety are observed at
m/z 77 and 105 for a nonsubstituted phenyl ring, at m/z 91
and 119 for a methylphenyl ring, and at m/z 121 and 149
for a methylenedioxyphenyl ring. Matsuta et al. [62]
demonstrated the detailed analysis of MS data obtained by
GC–EI-MS for identification of cathinones and specified
indexing information. However, the ionization rate of the
fragments in ring-substituted cathinones is remarkablyT
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weaker than that of the immonium ion. Other information
obtained by TOFMS or CI-MS is helpful to delineate the
molecular structure [63–66]. The identification of the re-
gioisomer of the fluorinated cathinones was demonstrated
using CI-MS [67]. However, this phenomenon was sug-
gested to be limited to these analogs.
The published methods for analysis of cathinones in
biological materials are summarized in Table 2 [68–79].
Simple LLE is usually used for extraction of cathinones from
biological materials. The chromatographic conditions are
also simple and do not usually require a special technique.
LC–MS-MS detection
The strategy for the detection of cathinones by LC–MS-MS
is almost same as that for synthetic cannabinoids; almost
all methods use MRM or SRM mode for sensitive deter-
mination. The probable fragmentation pathways are shown
in Fig. 5. The [M?H]? ion is selected as a precursor ion,
and three product ions that reflect the chemical structures
of the cathinones are selected. Using this method, 30–50
drugs are monitored simultaneously in samples [80–82].
The published methods for analysis of cathinones in bio-
logical materials are summarized in Table 3 [68, 69, 74,
75, 77, 79, 82–98]. Simple LLE is usually used for the
extraction of cathinones from biological materials. The
chromatographic conditions are also simple and do not
require a special technique.
In the same way as identification by GC–MS, other in-
formation obtained by TOFMS or tandem MS is needed to
clarify the molecular structure. An authentic drug or library
database is needed to identify the drugs. Moreover, the
probable fragmentation pathways of cathinones are de-
scribed in the previous articles [61, 65, 66, 99]. These data
are helpful in identifying the drugs.
As described in the section on synthetic cannabinoids, we
occasionally encounter a dubious product that contains more
than several milligrams of an unknown cathinone-like
compound. In such a case, GC–MS, LC–MS, high-resolution
MS (or TOFMS), and finally NMR spectroscopy are used to
clarify the detailed chemical structure of the compound.
Concentrations in the cases of abuse
Synthetic cannabinoids
The common method of consumption of synthetic
cannabinoids is smoking, which is the same as for con-
ventional cannabis. The maximum concentrations of syn-
thetic cannabinoids in serum are reached in less than
10 min after smoking [38]. The drugs absorbed in the body
are metabolized smoothly, and the concentrations decrease
rapidly. Moreover, there is also a report that cannabinoids
accumulate in the adipose tissue because of their high
lipophilicity [52]. Therefore, detection of the drug from
serum is usually difficult. Synthetic cannabinoids absorbed
in the human body are metabolized to hydroxyl or carboxyl
derivatives of the aromatic ring or N-alkyl side chain [100].
It is difficult to identify the parent drug and its metabolites
O
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Fig. 5 Probable fragmentation pathways of cathinones by electrospray ionization and electron ionization (modified from references [61, 62, 65,
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in blood by GC–MS alone because the fragmentation of the
metabolites is similar to that of the parent drug and ana-
logs. Moreover, the concentration of the unchanged syn-
thetic cannabinoids in blood is very low, and the number of
metabolites that are commercially available is small. Low
sensitivity is a limitation for the determination of synthetic
cannabinoids in blood by GC–MS.
Although the concentration is influenced by the sam-
pling time after drug intake and by the intake amount,
concentrations of these drugs in serum were reported in the
range of 0.1–190 ng/ml in poisoning cases [46]. In fatal
cases, the concentrations of the drugs in blood were
0.1–199 ng/ml for JWH-018 and 0.1–68.3 ng/ml for JWH-
073 [50], 12 ng/ml for AM-2201 [100], 1.1–1.5 ng/ml for
5F-PB-22 [53], and 12.4 ng/ml for MAM-2201 [52].
Cathinones
Unlike synthetic cannabinoids, the most common method
of consumption of cathinones are insufflation (snorting) or
ingestion. Inhalation, sublingual and rectal administration,
and intramuscular or intravenous injection have also been
reported. Unlike synthetic cannabinoids, the concentration
of cathinones in blood is thought to vary because of the
many modes of administration used by abusers. Only the
blood concentration at one point and at several points have
been quantified, and there is no report on continuous
monitoring of the profile of the drug concentration in
blood. The fatal concentration of the drug in blood was
reported to be around 400 ng/ml [75]. The stability of
cathinones in blood samples is clearly influenced by pH, as
well as in the final extracts. In blood samples preserved
with NaF/potassium oxalate, the measured concentrations
of cathinone, methcathinone, ethcathinone, mephedrone,
and flephedrone declined by ca. 30 % after 2 days of
storage at 20 C [82].
Some groups have studied the metabolic pathways of
cathinones [68, 94, 101–103]. Unlike synthetic cannabi-
noids, the parent cathinones are detected easily in biolo-
gical materials and are selected as the target because the
unchanged parent drugs are rapidly excreted in urine.
Cathinones are ionized in the body, and the reabsorption
rate is low in the kidney because of low hydrophobicity.
The excretion profile of a-PBP and a-PVP in human urine
was determined after an intravenous injection, and the
elimination half-life in urine was approximately 12 h.
Moreover, the excreted amount in urine was influenced by
urinary pH, like a psycho-stimulant [104]. To analyze these
drugs in biological materials, it is necessary to remove
endogenous substances from each sample and enrich the
content of the drug. As shown in Table 3, LLE is usually
used for extraction of the drugs from biological materials.
The quantification of the metabolites is important to predict
the hazardous properties of the metabolites. However, be-
cause there are few metabolites marketed, no detailed study
about their pharmacological activity or toxicity has been
conducted.
In fatal cases, the concentrations of the drugs in blood
were: 560–3,300 [72], 272 [105], and 60–1,120 ng/ml
[106] for methylone; 1.2–22 [107], 5.1 [108], and 5.5 lg/
ml [88] for mephedrone; 55.2 ng/ml for a-PBP [95]; 486
[73] and 654 ng/ml [109] for a-PVP; 180 ng/ml [98] for
PV9; 170 [70], 82 [110], 1,200 [74], 440 [75], 17–38 [92],
and 700 ng/ml [111] for MDPV.
Conclusions
The number of abusers of synthetic cannabinoids and
cathinones has increased remarkably worldwide. The che-
mical structures of the distributed drugs are skillfully
changed so that the drugs may pass through screenings for
detection. Simple screening methods are required for de-
tection of these drugs in seized and biological materials.
There are currently no commercial kits or devices for the
routine screening of these drugs. Colorimetric, immuno-
chemical, and chromatographic methods have been intro-
duced in this review; a suitable method must be chosen for
each laboratory. Although various human sample matrices
are available for testing, urine and blood are of the first
choices. However, many of these drugs, especially un-
changed synthetic cannabinoids, exist in urine and blood
for only a short period. Therefore, other matrices that can
prove the consumption of these drugs, such as hair and
saliva, are likely to receive more attention in the future.
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